Onyx Pharmaceuticals, Inc. (ONXX) Snubbing Amgen (AMGN) Paves Way for 89% Premium; Pfizer Inc. (PFE), Novartis AG (NVS) Throw Names Into Hat
7/2/2013 6:52:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Onyx Pharmaceuticals has rejected Amgen's takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset—the blood cancer drug Kyprolis.
Help employers find you! Check out all the jobs and post your resume.